Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 5/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2354063 | 0.88 | MAPT (0.41) | DRD1NOTUMCHEK1MAPT | |
| SCHEMBL2352663 | 0.87 | MAPT (0.43) | DRD1LMNANOTUMSMN1; SMN2CHEK1 | |
| SCHEMBL2352347 | 0.85 | ALOX12 (0.42) | DRD1PIK3R1PIK3CADYRK1ALMNA | |
| SCHEMBL2350128 | 0.84 | IKBKB (0.39) | DRD1LMNANOTUMSMN1; SMN2MAPT | |
| SCHEMBL2352300 | 0.84 | AKT2 (0.49) | DRD1LMNASMN1; SMN2CHEK1NPC1 | |
| SCHEMBL2352604 | 0.82 | NOTUM (0.39) | DRD1PIK3CANOTUMNPC1MAPT | |
| SCHEMBL2319405 | 0.81 | DRD1 (0.35) | DRD1CHEK1MAPT | |
| SCHEMBL3334292 | 0.81 | IKBKB (0.45) | DRD1NOTUM | |
| SCHEMBL1936292 | 0.81 | DRD1 (0.41) | DRD1PIK3R1PIK3CADYRK1AGSK3B | |
| SCHEMBL2348396 | 0.80 | IKBKB (0.44) | DRD1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008512-B2 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-20090281337-A1 | Pyridazine compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-11-12 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| US-7569518-B2 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1767529-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-1767529-B1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
| EP-1767529-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767529-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2007-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194566-A1 | Pyridazine Compound and Use Thereof | PLPBP, PNPO, CYP4Z1 | DRD1 1301/4885PIK3R1 2909/4885PIK3CA 2842/4885 |
| US-20090281337-A1 | Pyridazine compound and use thereof | PLPBP, PNPO, CYP4Z1 | DRD1 1301/4885PIK3R1 2909/4885PIK3CA 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.